EGFR and non-small cell lung carcinoma: Fortunately, the advancement of EGFR-TKIs dramatically revolutionized treatment strategies for a great proportion of NSCLC patients carrying EGFR mutations (Figure 1), which is the most common oncogenic mutations among Asians with lung adenocarcinoma (LUAD) [3,4,5].